# LISDEXAMFETAMINE DIMESYLATE
> **ANDA202802** · Abbreviated New Drug Application (Generic) · Sponsor: ACTAVIS ELIZABETH · Approved 2023-08-25
## Drug
- **FDA Application Number:** ANDA202802
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** LISDEXAMFETAMINE DIMESYLATE
- **Generic name:** LISDEXAMFETAMINE DIMESYLATE
- **Active ingredients:** LISDEXAMFETAMINE DIMESYLATE
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** ACTAVIS ELIZABETH
- **Manufacturer:** Teva Pharmaceuticals, Inc.
- **First approval:** 2023-08-25
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202802)
---
*AI Analytics · CC0 1.0*